共 15 条
[1]
[2]
[3]
Rapamycin ameliorates lipopolysaccharide-induced acute lung injury by inhibiting IL-1β and IL-18 production.[J].Xuehong Jia;Bin Cao;Yunqing An;Xulong Zhang;Chen Wang.International Immunopharmacology.2019,
[4]
Barbaloin protects against lipopolysaccharide (LPS)-induced acute lung injury by inhibiting the ROS-mediated PI3K/AKT/NF-κB pathway.[J].Kangfeng Jiang;Shuai Guo;Chao Yang;Jing Yang;Yu Chen;Aftab Shaukat;Gan Zhao;Haichong Wu;Ganzhen Deng.International Immunopharmacology.2018,
[6]
The protective effect of dexmedetomidine on LPS-induced acute lung injury through the HMGB1-mediated TLR4/NF-κB and PI3K/Akt/mTOR pathways.[J].Lu Meng;Longyun Li;Shan Lu;Kai Li;Zhenbo Su;Yunyun Wang;Xiaodi Fan;Xuyang Li;Guoqing Zhao.Molecular Immunology.2018,
[7]
3; 4-dihydroxybenzalacetone attenuates lipopolysaccharide-induced inflammation in acute lung injury via down-regulation of MMP-2 and MMP-9 activities through suppressing ROS-mediated MAPK and PI3K/AKT signaling pathways.[J].Wei Chao;Jeng-Shyan Deng;Shyh-Shyun Huang;Pei-Ying Li;Yu-Chia Liang;Guan-Jhong Huang.International Immunopharmacology.2017,
[10]
Anti-TNFα therapy in inflammatory lung diseases.[J].Rama Malaviya;Jeffrey D. Laskin;Debra L. Laskin.Pharmacology and Therapeutics.2017,

